Synageva BioPharma Reports First Quarter 2012 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today reported first quarter 2012 financial results, and provided data from a natural history study of infants with early onset LAL Deficiency that were recently presented at the 3rd International Congress for Lysosomal Diseases held in North Cyprus, Turkey.
MORE ON THIS TOPIC